Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrous glycine sulfate is an oral iron salt compound used as a mineral supplement for the treatment of iron deficiency anemia. It consists of iron (II) coordinated with the amino acid glycine. In clinical research conducted by Assiut University, it was evaluated in a Phase 4 trial (NCT02590224) for its efficacy and safety in pregnant women with mild to moderate anemia, where it was compared to ferrous bis-glycinate. The drug works by providing a source of elemental iron necessary for the synthesis of hemoglobin in red blood cells. While effective at increasing hemoglobin levels, studies have indicated it may be associated with higher rates of gastrointestinal side effects compared to chelated forms like ferrous bis-glycinate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous glycine sulfate.